Found 534 clinical trials
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
) and recommended Dose (RP2D) for HRS2300 monotherapy and combination therapy.
- 0 views
- 10 Nov, 2021
- 1 location
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
-TKI and decrease the related toxicity of the combination therapy.
- 0 views
- 27 Jan, 2021
- 20 locations
A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients
(Albumin Bound) for advanced solid tumors of patients. To explore the reasonable dosage of dosage regimen of combination therapy for advanced malignant tumors of patients.
- 0 views
- 27 Apr, 2022
- 1 location
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
The purpose of this study is to evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or
- 0 views
- 22 Jul, 2022
- 1 location
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA)
benefit of combination therapy for patients with OCCC.
- 0 views
- 16 May, 2022
- 1 location
EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone
The purpose of this study is to evaluate the efficacy of combination therapy with omeprazole and swallowed fluticasone vs fluticasone therapy and placebo in the treatment of Eosinophilic
- 0 views
- 22 Jan, 2021
- 1 location
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma
This study is to investigate safety and feasibility of a combination therapy of a tumor infiltrating lymphocytes (TIL) transfer with anti-programmed cell death protein (PD)-1 therapy in patients
- 0 views
- 14 Aug, 2021
- 1 location
Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC
combination therapy with pembrolizumab and MS-20.
- 6 views
- 16 Oct, 2021
- 2 locations
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen
- 0 views
- 13 Mar, 2022
- 1 location
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
and PD-L1 CPS≥5 ) will receive HLX07 combination therapy with HLX10 and chemotherapy (oxaliplatin+capecitabine) as first-line treatment. Arm B will receive HLX07 monotherapy as third-line or above
- 0 views
- 16 May, 2022
- 2 locations